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OBJECTIVES: The PROVE IT-TIMI 22 trial demonstrated clin-
ical beneﬁt of intensive lipid lowering (atorvastatin 80 mg) vs.
moderate lipid lowering (pravastatin 40 mg) in patients with
acute coronary syndrome (ACS). Prior US analysis found lower
net costs for intensive Rx. The objective of this analysis was to
evaluate cost-effectiveness of intensive vs. moderate statin
therapy in ACS patients in the UK, Germany and Canada where
generic pravastatin is available and hospitalization costs lower
than in the US. METHODS: Hospitalization and length of treat-
ment were obtained from PROVE-IT case report forms. Hospi-
talizations were classiﬁed by relevant DRG system and
multiplied by associated hospitalization costs in the UK,
Germany and Canada. Drug costs were obtained from each
country’s public or tariff prices. RESULTS: Compared with mod-
erate pravastatin therapy, intensive atorvastatin therapy was
associated with fewer hospitalizations (1301 vs. 1444; 0.62/pt
vs. 0.70/pt). Total costs (hospital + drug) per patient of intensive
vs. moderate therapy were ≤3184 vs. ≤3236 (UK), €5242 vs.
€5515 (Germany) and CA$7386 vs. CA$8087 (Canada), with
savings per patient of ≤56, €284 and CA$701 respectively over
the 2-year study period. Thus, increased drug acquisition costs
were more than offset by reduced hospitalization costs in all
three countries. Sensitivity analysis on treatment pattern varia-
tions, events and costs will be conducted. If the PROVE-IT
results are generalizable to all ACS patients, the savings from
intensive vs. moderate statin therapy per two years of treatment
would be £5.6 million, €28.4 million and CA$70.1 million for
every 100,000 ACS patients in the UK, Germany and Canada,
respectively. CONCLUSIONS: As observed in PROVE-IT, inten-
sive atorvastatin therapy reduced clinical events and costs com-
pared to moderate pravastatin therapy among ACS patients in
the UK, Germany and Canada and thus is clinically beneﬁcial at
a lower overall cost among PROVE-IT ACS patients, allowing
allocation of resources to other therapy options.
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OBJECTIVE: Often cost-effectiveness analyses must be under-
taken before a price for the product has been set. This study eval-
uated the expected cost-effectiveness of rimonabant, the ﬁrst
selective CB-1 receptor blocker, for treatment of patients with
dyslipidemia in the UK under various price assumptions.
METHODS: A Markov model (SHAPE) was developed using
data from clinical trials, published risk equations and UK patient
proﬁles from the Health Outcomes Data Repository Database
(HODaR) registry. Patients transition from At Risk or Diabetes
to CVD based on UKPDS 68 or Framingham Heart study 
equations, or to death based on UK life-tables, and to diabetes 
(San Antonio Heart study) and subsequent CVD events
(Saskatchewan equations). UK costs for acute resource use upon
transition as well as longer term routine management are accrued
in 2005 GBP. Age-dependent utilities are calculated and tariffs
for all events and states are applied. Rimonabant effects on car-
diometabolic risk factors were taken from the RIO Lipids trial.
Ten year and lifetime horizons were examined; all outcomes were
discounted at 3.5%/yr. Extensive probabilistic sensitivity analy-
ses were carried out. RESULTS: Over ten years, >13% of
patients are expected to suffer a cardiovascular event with a loss
of more than 1045 QALYs and a cost above £600,000 per 1000
patients. Adding rimonabant to diet & exercise for only one year
is estimated to gain >100 QALYs over a lifetime. Preliminary
cost-effectiveness ratios remained acceptable (less then
≤20,000/QALY) under a wide range of assumptions and when
testing hypothetical prices as high as ≤8 per day. CONCLU-
SIONS: Based on the reductions in total to HDL cholesterol
ratio, weight and other risk factors seen in RIO Lipids trial,
rimonabant should substantially reduce cardiovascular risk in
obese or overweight patients with dyslipidemia and result in an
acceptable cost-effectiveness ratio.
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OBJECTIVES: 1) To quantify and characterize the cost-utility
analyses (CUAs) published in the scientiﬁc literature through
2003; and 2) to examine methodological practices used in these
CUAs. This paper builds upon our previous analyses that eval-
uated CUAs from 1976 through 2001. METHODS: We system-
atically searched Medline and the Health Economic Evaluations
Database (HEED) for original CUAs written in English and pub-
lished during 2002–2003 to update a comprehensive registry of
CUAs (www.tufts-nemc.org/cearegistry). Two trained readers
independently extracted data on the characteristics and method-
ology of each study. We compared recently published
(2002–2003) with previously published (1976–2001) data.
RESULTS: Our previous search identiﬁed 533 original CUAs
published during 1976–2001; a ﬁnding of 262 studies published
during 2002–2003 increased the sample by almost 50%. In the
1976–2001 and 2002–2003 data, most studies were based in the
US (61%, 53%) and written by academics (90%, 92%). Studies
examined treatment (63%, 62%) more than primary (14%,
16%) and secondary (22%, 21%) prevention. The most frequent
condition studied was cardiovascular disease (21%, 18%). Per-
centage of funding by the pharmaceutical and device industry
did not change substantially (19%, 23%). Studies improved with
time across the two datasets: disclosing funding source (65% vs.
71%), stating year of currency (76% vs. 82%), reporting incre-
mental ratios (59% vs. 79%), and using probabilistic sensitivity
analyses (9% vs. 28%). CONCLUSIONS: The publication of
